FDA Finalizes Guidance on Interoperable Medical Devices

McGuireWoods LLP
Contact
Recently, the U.S. Food and Drug Administration (FDA) finalized guidance summarizing its recommendations for interoperable medical devices, or devices that are connected to each other and to other technology. Noting the growing need and desire to connect medical devices to each other as well as other products, including products from different manufactures, FDA highlighted the devices’ potential to foster rapid innovation.

On the other hand, FDA pointed out that failure to address appropriate safety considerations in the device design can result in “unforeseen safety and effectiveness issues for the patient, operator, device or system.” Specifically, FDA pointed to various risks associated with connected devices, such as errors stemming from inadequate interoperability or the exchange of inaccurate, untimely or misleading information. Device malfunction, which could lead to patient injury or even death, is another concern for the agency.

Accordingly, FDA summarized its recommendations for device design and premarket submissions for device manufacturers. FDA said manufactures should clearly set forth in device labeling the functional and performance requirements of their electronic interface to minimize risks associated with failure to exchange and use data as intended. Moreover, manufacturers should identify the anticipated users of the electronic interface, and design the device and its electronic interface with this user population in mind. Manufacturers also should include risk management and verification and validation mechanisms as part of the design process.

As with all FDA guidance, this document is not binding on the industry and does not constitute regulation. However, it does represent FDA’s current thinking on this topic. As more interoperable devices are developed, FDA’s views likely will continue to evolve. FDA’s associate director for digital health in FDA’s Center for Devices and Radiological Health noted that FDA’s guidance is a “good step towards safer devices, and [FDA] will continue to work with all stakeholders to adapt along with the technology.”

 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations. Attorney Advertising.

© McGuireWoods LLP

Written by:

McGuireWoods LLP
Contact
more
less

PUBLISH YOUR CONTENT ON JD SUPRA NOW

  • Increased visibility
  • Actionable analytics
  • Ongoing guidance

McGuireWoods LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide